Combined Tests Provide Better Asthma Diagnosis
By LabMedica International staff writers Posted on 10 Oct 2013 |

Image: Three eosinophils in a peripheral blood smear from a patient with eosinophilia (Photo courtesy of Ed Uthman, MD).
Fraction of exhaled nitric oxide (FENO) and blood eosinophil-count values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients.
Measurement of the concentration of exhaled nitric oxide is today a routine clinical method for determining the degree of steroid-sensitive inflammation in the airways in asthma and for many years, a count of eosinophil granulocytes in the blood has also been used to support a diagnosis of asthma.
Scientists at Uppsala University (Sweden) measured FENO and eosinophil values in 12,408 subjects aged 6 to 80 years from 2007 to 2008 and from 2009 to 2010. Current wheeze and asthma diagnosis, as well as asthma attacks and asthma-related emergency department (ED) visits within the last 12 months, were assessed by means of questionnaires.
The FENO values were measured with the NIOX MINO electrochemical analyzer (Aerocrine AB; Solna, Sweden) at an expiratory flow rate of 50 mL/second. Blood differential counts were performed by using the automated HmX hematology analyzer (Beckman Coulter; Fullerton, CA, USA). The following cutoffs for eosinophil values were used: less than 300 cells/mm3 to define normal values; 300 cells/mm3 or greater but less than 500 cells/mm3 for intermediate values and 500 cells/mm3 or greater for high values, as this is the limit for defining eosinophilia.
The scientists were able to determine that the association between FENO and blood eosinophils was very weak. Instead, they observed that simultaneously elevated levels of the two markers, in a synergistic way, but independently of each other, increased the likelihood of individuals reporting, for example, asthma symptoms or asthma attacks in the last year. The results supported their hypothesis that the two markers represent two different inflammation processes.
Kjell Alving, PhD, a professor at the Department of Children's and Women's Health, Uppsala University, and a senior author of the study said, “We therefore propose that both of these measurements be carried out in combination in order to better understand the inflammation in asthma patients. They thus constitute a better platform for selecting the proper treatment for these patients.” The study was published in the October 2013 issue of the Journal of Allergy and Clinical Immunology.
Related Links:
Uppsala University
Aerocrine AB
Beckman Coulter
Measurement of the concentration of exhaled nitric oxide is today a routine clinical method for determining the degree of steroid-sensitive inflammation in the airways in asthma and for many years, a count of eosinophil granulocytes in the blood has also been used to support a diagnosis of asthma.
Scientists at Uppsala University (Sweden) measured FENO and eosinophil values in 12,408 subjects aged 6 to 80 years from 2007 to 2008 and from 2009 to 2010. Current wheeze and asthma diagnosis, as well as asthma attacks and asthma-related emergency department (ED) visits within the last 12 months, were assessed by means of questionnaires.
The FENO values were measured with the NIOX MINO electrochemical analyzer (Aerocrine AB; Solna, Sweden) at an expiratory flow rate of 50 mL/second. Blood differential counts were performed by using the automated HmX hematology analyzer (Beckman Coulter; Fullerton, CA, USA). The following cutoffs for eosinophil values were used: less than 300 cells/mm3 to define normal values; 300 cells/mm3 or greater but less than 500 cells/mm3 for intermediate values and 500 cells/mm3 or greater for high values, as this is the limit for defining eosinophilia.
The scientists were able to determine that the association between FENO and blood eosinophils was very weak. Instead, they observed that simultaneously elevated levels of the two markers, in a synergistic way, but independently of each other, increased the likelihood of individuals reporting, for example, asthma symptoms or asthma attacks in the last year. The results supported their hypothesis that the two markers represent two different inflammation processes.
Kjell Alving, PhD, a professor at the Department of Children's and Women's Health, Uppsala University, and a senior author of the study said, “We therefore propose that both of these measurements be carried out in combination in order to better understand the inflammation in asthma patients. They thus constitute a better platform for selecting the proper treatment for these patients.” The study was published in the October 2013 issue of the Journal of Allergy and Clinical Immunology.
Related Links:
Uppsala University
Aerocrine AB
Beckman Coulter
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
- Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more